ARVN Quote, Financials, Valuation and Earnings

Genprex, Inc. has a net margin of -83.77% compared to Arvinas, Inc.'s net margin of --. Arvinas, Inc.'s return on equity of -9.81% beat Genprex, Inc.'s return on equity of -900.4%.

Arvinas, Inc. has a consensus price target of $12.44, signalling upside risk potential of 2.28%. On the other hand Genprex, Inc. has an analysts' consensus of $7.50 which suggests that it could grow by 20849.72%. Given that Genprex, Inc. has higher upside potential than Arvinas, Inc., analysts believe Genprex, Inc. is more attractive than Arvinas, Inc..

Arvinas, Inc. has a beta of 2.446, which suggesting that the stock is 144.578% more volatile than S&P 500. In comparison Genprex, Inc. has a beta of -0.771, suggesting its less volatile than the S&P 500 by 177.148%.

Arvinas, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genprex, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arvinas, Inc. pays -- of its earnings as a dividend. Genprex, Inc. pays out -- of its earnings as a dividend.

Arvinas, Inc. quarterly revenues are $41.9M, which are larger than Genprex, Inc. quarterly revenues of --. Arvinas, Inc.'s net income of -$35.1M is lower than Genprex, Inc.'s net income of -$3.8M. Notably, Arvinas, Inc.'s price-to-earnings ratio is -- while Genprex, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas, Inc. is 2.83x versus -- for Genprex, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -83.77% compared to Arvinas, Inc.'s net margin of 21.32%. Arvinas, Inc.'s return on equity of -9.81% beat Pfizer Inc.'s return on equity of 10.84%.

Arvinas, Inc. has a consensus price target of $12.44, signalling upside risk potential of 2.28%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.08%. Given that Pfizer Inc. has higher upside potential than Arvinas, Inc., analysts believe Pfizer Inc. is more attractive than Arvinas, Inc..

Arvinas, Inc. has a beta of 2.446, which suggesting that the stock is 144.578% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Arvinas, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.86% to investors and pays a quarterly dividend of $0.43 per share. Arvinas, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Arvinas, Inc. quarterly revenues are $41.9M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Arvinas, Inc.'s net income of -$35.1M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Arvinas, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas, Inc. is 2.83x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics, Inc. has a net margin of -83.77% compared to Arvinas, Inc.'s net margin of -45.06%. Arvinas, Inc.'s return on equity of -9.81% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.

Arvinas, Inc. has a consensus price target of $12.44, signalling upside risk potential of 2.28%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $20.61 which suggests that it could fall by -6.83%. Given that Arvinas, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Arvinas, Inc. is more attractive than Sarepta Therapeutics, Inc..

Arvinas, Inc. has a beta of 2.446, which suggesting that the stock is 144.578% more volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.537, suggesting its less volatile than the S&P 500 by 46.348%.

Arvinas, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arvinas, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.

Arvinas, Inc. quarterly revenues are $41.9M, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. Arvinas, Inc.'s net income of -$35.1M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, Arvinas, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas, Inc. is 2.83x versus 0.95x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Verastem, Inc. has a net margin of -83.77% compared to Arvinas, Inc.'s net margin of -876.34%. Arvinas, Inc.'s return on equity of -9.81% beat Verastem, Inc.'s return on equity of -1773.4%.

Arvinas, Inc. has a consensus price target of $12.44, signalling upside risk potential of 2.28%. On the other hand Verastem, Inc. has an analysts' consensus of $16.00 which suggests that it could grow by 98.51%. Given that Verastem, Inc. has higher upside potential than Arvinas, Inc., analysts believe Verastem, Inc. is more attractive than Arvinas, Inc..

Arvinas, Inc. has a beta of 2.446, which suggesting that the stock is 144.578% more volatile than S&P 500. In comparison Verastem, Inc. has a beta of 0.412, suggesting its less volatile than the S&P 500 by 58.798%.

Arvinas, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arvinas, Inc. pays -- of its earnings as a dividend. Verastem, Inc. pays out -- of its earnings as a dividend.

Arvinas, Inc. quarterly revenues are $41.9M, which are larger than Verastem, Inc. quarterly revenues of $11.2M. Arvinas, Inc.'s net income of -$35.1M is higher than Verastem, Inc.'s net income of -$98.5M. Notably, Arvinas, Inc.'s price-to-earnings ratio is -- while Verastem, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas, Inc. is 2.83x versus 37.66x for Verastem, Inc.. Usually stocks with elevated PS ratios are considered overvalued.